SIM 0508
Alternative Names: SIM-0508Latest Information Update: 15 Jul 2026
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA polymerase theta inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Jul 2026 Phase-I clinical trials in Solid tumours in USA (PO), prior to July 2026 (Simcere Pharmaceutical Group pipeline, July 2026)
- 06 Dec 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in China (unspecified route) (NCT06686745)
- 06 Dec 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in China (unspecified route) (NCT06686745)